Table 2.
Demographics, clinical, imaging and treatment details of 22 patients with giant cell arteritis treated with tocilizumab
| No. | Age | Sex | GCA type | Confirmatory test | Prior csDMARD |
Disease duration prior TCZ (months) | TCZ indication | TCZ treatment | Outcome | Prednisolone, dose at TCZ start | Prednisolone, lowest dose during TCZ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 66 | F | LVV | US+PET | MMF | 19 | Refractory | Continuous | Remission | 40 mg | 2.5 mg |
| 2 | 73 | F | LVV | US+PET | MTX +AZA | 39 | Relapse | Continuous | Remission | 20 mg | 3.75 mg |
| 3 | 70 | F | LVV | US+PET | LEF | 14 | Relapse | Continuous | Remission | 15 mg | 2.5 mg |
| 4 | 84 | M | Cranial | US | 2 | Ischaemia | Continuous | Remission | 20 mg | 6 mg | |
| 5 | 72 | F | Both | US+TAB | 1 | Ischaemia | Continuous | Remission | 20 mg | 2.5 mg | |
| 6 | 70 | F | LVV | US+PET | LEF | 28 | Refractory | Discontinued | Remission | 20 mg | 1 mg |
| 7 | 75 | M | Cranial | US | 4 | Ischaemia | Continuous | Remission | 60 mg | 2.5 mg | |
| 8 | 70 | M | Cranial | US | 3 | Ischaemia | Interrupted | Remission | 60 mg | 15 mg | |
| 9 | 71 | F | LVV | US+PET | MTX | 35 | Refractory | Completed | Active | 60 mg | 2.5 mg |
| 10 | 77 | F | Cranial | US | 2 | Refractory | Continuous | Remission | 50 mg | 2.5 mg | |
| 11 | 59 | F | Cranial | US | 2 | Ischaemia | Completed | Remission | 60 mg | 2.5 mg | |
| 12 | 60 | M | LVV | US+PET | LEF | 15 | Refractory | Continuous | Remission | 10 mg | 0 mg |
| 13 | 75 | F | Both | US+TAB | MTX | 16 | Refractory | Discontinued | Active | 60 mg | 8.75 mg |
| 14 | 84 | F | Cranial | US+TAB | 0 | Ischaemia | Completed | Remission | 40 mg | 5 mg | |
| 15 | 69 | M | LVV | US+TAB+PET | MMF | 42 | Refractory | Completed | Remission | 30 mg | 0 mg |
| 16 | 68 | F | Cranial | US+TAB | MTX+LEF | 92 | Relapse | Continuous | Remission | 20 mg | 2 mg |
| 17 | 66 | M | LVV | US+PET | LEF | 20 | Refractory | Continuous | Remission | 20 mg | 15 mg |
| 18 | 76 | F | Cranial | US | 4 | Ischaemia | Continuous | Remission | 60 mg | 0 mg | |
| 19 | 71 | M | Cranial | US | 37 | Ischaemia | Continuous | Remission | 20 mg | 2.5 mg | |
| 20 | 88 | M | Cranial | US+TAB | 12 | Refractory | Continuous | Remission | 30 mg | 12.5 mg | |
| 21 | 71 | F | LVV | US+PET | LEF | 21 | Refractory | Continuous | Remission | 7.5 mg | 7.5 mg |
| 22 | 70 | F | LVV | PET | 3 | Refractory | Continuous | Remission | 30 mg | 0 mg |
AZA, azathioprine; csDMARD, conventional synthetic disease-modifying antirheumatic drug; GCA, giant cell arteritis; LEF, leflunomide; LVV: large vessel vasculitis; MTX, methotrexate; MMF, mycophenolate mofetil; PET: position emission tomography; TCZ: tocilizumab; US: ultrasound.